Ahoon
2021-12-07
Nice
AstraZeneca to Work with Ionis on Eplontersen Drug
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":606200817,"tweetId":"606200817","gmtCreate":1638879786943,"gmtModify":1638879787059,"author":{"id":3581765272832510,"idStr":"3581765272832510","authorId":3581765272832510,"authorIdStr":"3581765272832510","name":"Ahoon","avatar":"https://static.tigerbbs.com/81bb43fa20e6b2aea2bff0c8696c78c9","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/606200817","repostId":1168326906,"repostType":4,"repost":{"id":"1168326906","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638878102,"share":"https://www.laohu8.com/m/news/1168326906?lang=&edition=full","pubTime":"2021-12-07 19:55","market":"us","language":"en","title":"AstraZeneca to Work with Ionis on Eplontersen Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1168326906","media":"Dow Jones","summary":"AstraZeneca PLC said Tuesday that it will collaborate with Ionis Pharmaceuticals Inc., to jointly de","content":"<p></p>\n<p>AstraZeneca PLC said Tuesday that it will collaborate with Ionis Pharmaceuticals Inc., to jointly develop and commercialize the Californian biotechnology company's antisense drug Eplontersen.</p>\n<p>The companies will jointly develop and commercialize the drug in the U.S., while AstraZeneca will develop and commercialize Eplontersen in the rest of the world, except for Latin America, it said.</p>\n<p>The pharmaceutical company will pay Ionis $200 million up front and additional conditional payments of up to $485 million after regulatory approvals. It will also pay up to $2.9 billion of sales-related milestones, and royalties in the range of a low double-digit to a mid-twenties percentage, depending on the region.</p>\n<p>Eplontersen, which is currently in phase 3 clinical trials, treats amyloid transthyretin cardiomyopathy, or ATTR-CM--a systemic, progressive and fatal condition that leads to progressive heart failure and death within four years of diagnosis. It also treats amyloid transthyretin polyneuropathy, or ATTR-PN, a disease causing peripheral nerve damage with motor disability within five years of diagnosis, and is generally fatal within a decade if untreated.</p>\n<p>Hereditary ATTR-PN treatment is likely to be the first regulatory approval for Eplontersen, with the potential to file a new drug application with the U.S. Food and Drug Administration by the end of 2022.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca to Work with Ionis on Eplontersen Drug </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca to Work with Ionis on Eplontersen Drug \n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-07 19:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p></p>\n<p>AstraZeneca PLC said Tuesday that it will collaborate with Ionis Pharmaceuticals Inc., to jointly develop and commercialize the Californian biotechnology company's antisense drug Eplontersen.</p>\n<p>The companies will jointly develop and commercialize the drug in the U.S., while AstraZeneca will develop and commercialize Eplontersen in the rest of the world, except for Latin America, it said.</p>\n<p>The pharmaceutical company will pay Ionis $200 million up front and additional conditional payments of up to $485 million after regulatory approvals. It will also pay up to $2.9 billion of sales-related milestones, and royalties in the range of a low double-digit to a mid-twenties percentage, depending on the region.</p>\n<p>Eplontersen, which is currently in phase 3 clinical trials, treats amyloid transthyretin cardiomyopathy, or ATTR-CM--a systemic, progressive and fatal condition that leads to progressive heart failure and death within four years of diagnosis. It also treats amyloid transthyretin polyneuropathy, or ATTR-PN, a disease causing peripheral nerve damage with motor disability within five years of diagnosis, and is generally fatal within a decade if untreated.</p>\n<p>Hereditary ATTR-PN treatment is likely to be the first regulatory approval for Eplontersen, with the potential to file a new drug application with the U.S. Food and Drug Administration by the end of 2022.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168326906","content_text":"AstraZeneca PLC said Tuesday that it will collaborate with Ionis Pharmaceuticals Inc., to jointly develop and commercialize the Californian biotechnology company's antisense drug Eplontersen.\nThe companies will jointly develop and commercialize the drug in the U.S., while AstraZeneca will develop and commercialize Eplontersen in the rest of the world, except for Latin America, it said.\nThe pharmaceutical company will pay Ionis $200 million up front and additional conditional payments of up to $485 million after regulatory approvals. It will also pay up to $2.9 billion of sales-related milestones, and royalties in the range of a low double-digit to a mid-twenties percentage, depending on the region.\nEplontersen, which is currently in phase 3 clinical trials, treats amyloid transthyretin cardiomyopathy, or ATTR-CM--a systemic, progressive and fatal condition that leads to progressive heart failure and death within four years of diagnosis. It also treats amyloid transthyretin polyneuropathy, or ATTR-PN, a disease causing peripheral nerve damage with motor disability within five years of diagnosis, and is generally fatal within a decade if untreated.\nHereditary ATTR-PN treatment is likely to be the first regulatory approval for Eplontersen, with the potential to file a new drug application with the U.S. Food and Drug Administration by the end of 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":668,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/606200817"}
精彩评论